Gemcitabine-associated thrombotic microangiopathy – a role for eculizumab?

Teresa Chuva1, Ana Ferreira2, José Maximino1, Rui Henrique3, Ana Paiva1, Alfredo Loureiro1

1 Serviço de Nefrologia do Instituto Português de Oncologia do Porto
2 Serviço de Oncologia Médica do Instituto Português de Oncologia do Porto
3 Serviço de Anatomia Patológica do Instituto Português de Oncologia do Porto

INTRODUCTION

Thrombotic microangiopathy (TMA) is characterized by arteriolar and capillary thrombosis due to endothelial damage and its clinical manifestations are hemolytic anemia, thrombocytopenia, and organ injury, such as kidney failure. TMA may present as diverse syndromes. When it results from dysregulation of the alternative pathway of complement, it is commonly known as "atypical" hemolytic uremic syndrome (aHUS). It may be secondary to drugs or a coexisting disease, such as cancer, and a variety of medicines have been implicated, including different antineoplastic agents. Gemcitabine-associated thrombotic microangiopathy (gTMA), although considered a rare entity, has been described in many reports since its initial use, often associated with a poor prognosis. The advent of the new anti-C5 monoclonal antibody eculizumab has brought promising results and offers a potential therapeutic option for gTMA.

CASE PRESENTATION

A 54-year-old Caucasian woman with a synovial sarcoma of the leg was started on weekly gemcitabine (1000mg/m² per dose) because of recurrent disease. She had pulmonary metastasis and previously been treated with doxorubicin, ifosfamide, trabectedin and pazopanib. Her medical history was notable for rheumatoid arthritis that had been stable without medication for more than 10 years. During her fourth cycle of gemcitabine (cumulative dose 15.990mg), she presented with pancytopenia that caused her to suspend treatment. Two weeks later, she developed new-onset hypertension (blood pressure 173/101mmHg) and acute kidney injury (AKI) with serum creatinine (Scr) 2.04mg/dL (reference range 0.51–0.95mg/dL). She was hospitalized after another week for hypertension, AKI, anemia and thrombocytopenia, all consistent with gTMA. Her ECOG Performance Status was 0 and she was still professionally active. The laboratory tests on admission were: Scr 5.8mg/dL; lactate dehydrogenase (LDH) 1979U/L (reference range 67–248U/L); hemoglobin 5.8g/dL (reference range 11.5–16.5g/dL); platelets 51 x 10⁹/L (reference range 150–400 x 10⁹/L); total bilirubin 1.6mg/dL (reference range <1mg/dL), and haptoglobin <5.83mg/dL (reference range 36–195mg/dL). A peripheral blood smear showed the presence of schistocytes. Coagulation tests, ADAMTS13 activity, c3 and c4 levels of the complement system were normal. CH50 and AH50 levels were not measured. Further immunologic tests were within normal ranges. Her kidney function, anemia and thrombocytopenia continued to worsen during the following days. A kidney biopsy was performed, and she was started on hemodialysis. The histologic examination showed acute tubular injury with simplified epithelium, arteriolar fibrinoid thrombosis and narrowing due to intimal edema and laminator, glomerular fibrinoid necrosis and ischemic collapse of the capillary tufts [Figure 1]. Immunofluorescence showed no glomerular or tubular staining for IgA, IgG, IgM, C3 or C1q. Genetic testing for complement mutations (CFH, CD46 [MCP], CFI, C3, THBD, CFB,CFHR5, CFHR1 CFHR3, CFHR4, DGKE) was negative.

A diagnosis of gTMA was made and gemcitabine was stopped. After the patient started hemodialysis, hemolysis markers improved, with
stabilization of anemia and thrombocytopenia, normalization of bilirubin levels and decreasing LDH levels, but kidney function did not recover during the following weeks. Due to inconsistent results of plasmapheresis in the literature and no evidence of a circulating antibody or factor in gTMA, and after weighing potential risks and benefits, we decided against this treatment option. We agreed to start eculizumab therapy and the first dose was administered 33 days after the beginning of dialysis. The patient received 900mg every week for 4 doses, followed by 2 doses of eculizumab 1200mg at weeks 5 and 7. Prophylaxis of meningococcal infections was made with meningococcal vaccination (Men-ACW135Y and MenB). Although, ideally, it should be given at least 2 weeks before treatment, it was only started after the first dose of eculizumab. Antibiotic prophylaxis was administered with amoxicillin 500 mg twice daily throughout the treatment and until 60 days after the last eculizumab treatment. Other prophylaxis included the following vaccinations: Pn13, Hib and Influenza.

Her kidney function started to improve after the second dose of eculizumab and she had her last session of dialysis 10 days after the beginning of treatment. 5 months after the last hemodialysis, her creatinine was 0.96 mg/dL. Her blood pressure improved, but she continued dependent on antihypertensive drugs. At the time, she was proposed for chemotherapy with paclitaxel, but it was stopped 20 days later, after a septic episode requiring hospital admission. 10 months later, the patient died because of tumor progression. Her kidney function was normal.

**DISCUSSION**

gTMA is a well-described entity that led to a boxed warning in the product labeling of gemcitabine. It was first documented by Casper et al. in 1994 and remains a rare but potentially lethal condition. Its incidence has been estimated to vary between 0.008% and 0.078% based on the manufacturer’s safety database, yet it is possible that the reported incidence increases as clinicians become more aware of this diagnostic possibility.

The mechanisms underlying gTMA have not been fully elucidated and several hypotheses have been suggested, including an immune-associated response or a dose-dependent direct toxic reaction with damage of the endothelial cells and activation of platelet aggregation and intravascular hemolysis. No antibodies have been detected.
so far in gTMA and recent evidence suggests probable activation of the alternative pathway of complement, resembling the pathophysiology of aHUS. The onset is usually gradual after a median cumulative dose of 22 g/m² (range 4–81 g/m²) given over 7.5 months (range 2–34 months). In our patient, both the cumulative dose and time interval until gTMA were within this range. Other reports also describe new-onset or worsening hypertension preceding the diagnosis of gTMA, which we could also observe in this case.

The beginning of treatment depends on the recognition of TMA. Although usually mild and transitory, gemcitabine is associated with myelosuppression, which may delay the diagnosis. With our patient, other laboratory signs of hemolysis (elevated LDH, schistocytes, low haptoglobin, hiperbilirubinemia) contributed to the diagnosis of TMA and a kidney biopsy additionally helped with the differential diagnosis. Thrombotic thrombocytopenic purpura was excluded based on normal levels of ADAMTS13. Normal coagulation
studies made disseminated intravascular coagulation an unlikely diagnosis. Once gTMA was established, gemcitabine was discontinued, as recommended. Support therapy such as dialysis should be given if necessary. Further treatment strategies have varied over the years. Glucocorticoids, intravenous immunoglobulin, plasma infusion and rituximab have been used, with no proven benefit and inconsistent results. Eculizumab is a monoclonal antibody directed against C5 complement protein that has been approved for aHUS. Previous suspended, we decided to stop eculizumab after 4 initial induction doses plus another 2 for maintenance therapy, with no further complications. The same limited treatment time had also been tried by other authors with successful results. The duration of treatment has also been a matter of debate. Since genetic studies were normal and the offending drug had been suspended, we decided to stop eculizumab after 4 initial induction doses plus another 2 for maintenance therapy, with no further complications. The same limited treatment time had also been tried by other authors with successful results. The financial burden of eculizumab should be taken into consideration when treating an oncological patient. Despite having a cancer with a bad prognosis, our patient had an ECOG Performance Status of 0 and still had other possible treatment options available, which weighed on our decision. She lived for another 15 months after stopping dialysis. The quality of life of those months was highly improved thanks to the recovery of her kidney function after eculizumab. Despite the promising results with eculizumab in gTMA, other authors describe less favorable outcomes. However, these also depend on the evolution of the underlying malignant disease and its possible complications, which should not be underestimated and may interfere with any positive results.

More studies are needed to definitely access the benefit of eculizumab in gTMA, its indications and treatment duration.

CONCLUSION

gTMA is a rare event that often leads to the loss of kidney function and has potentially lethal consequences. Treatment options have varied over time, with inconsistent results. Although further studies are needed to validate this strategy, eculizumab should be considered as a possible first-line therapy.

Disclosure of potential conflicts of interest: none declared

References

Correspondence to:
Teresa Chuva
Nephrology Department, Instituto Português de Oncologia do Porto
E-mail: m.teresa.chuva@gmail.com